![Blood & Clots Series: How do I determine if my patient on a DOAC is still at increased risk of bleeding? - CanadiEM Blood & Clots Series: How do I determine if my patient on a DOAC is still at increased risk of bleeding? - CanadiEM](https://canadiem.org/wp-content/uploads/2019/09/Blog-44-Finalized-1.png.webp)
Blood & Clots Series: How do I determine if my patient on a DOAC is still at increased risk of bleeding? - CanadiEM
![Apixaban anti-Xa activity (ng/mL) and clinical characteristics for the... | Download Scientific Diagram Apixaban anti-Xa activity (ng/mL) and clinical characteristics for the... | Download Scientific Diagram](https://www.researchgate.net/publication/321762744/figure/tbl1/AS:775712122363904@1561955590351/Apixaban-anti-Xa-activity-ng-mL-and-clinical-characteristics-for-the-entire-group-and.png)
Apixaban anti-Xa activity (ng/mL) and clinical characteristics for the... | Download Scientific Diagram
![Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group](https://i0.wp.com/pharmaceuticalintelligence.com/wp-content/uploads/2020/07/wc-3.png?resize=500%2C308&ssl=1)
Do Novel Anticoagulants Affect the PT/INR? The Cases of XARELTO (rivaroxaban) and PRADAXA (dabigatran) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
![Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels - Scott J. Dingus, Alex R. Smith, William E. Dager, Sara Zochert, Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels - Scott J. Dingus, Alex R. Smith, William E. Dager, Sara Zochert,](https://journals.sagepub.com/cms/10.1177/10600280221090211/asset/images/large/10.1177_10600280221090211-fig2.jpeg)
Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels - Scott J. Dingus, Alex R. Smith, William E. Dager, Sara Zochert,
![Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know - Conway - 2017 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know - Conway - 2017 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library](https://accpjournals.onlinelibrary.wiley.com/cms/asset/3467d178-a6da-4a79-888e-1ee3a8b6d20e/phar.2017.37.issue-2.cover.jpg?trick=1677448186758)
Laboratory and Clinical Monitoring of Direct Acting Oral Anticoagulants: What Clinicians Need to Know - Conway - 2017 - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Wiley Online Library
![UPDATE ON THE DIRECT ORAL ANTICOAGULANTS (DOACs): WHERE ARE WE IN THE LABORATORY ALMOST TEN YEARS LATER? - DiaPharma UPDATE ON THE DIRECT ORAL ANTICOAGULANTS (DOACs): WHERE ARE WE IN THE LABORATORY ALMOST TEN YEARS LATER? - DiaPharma](https://diapharma.com/wp-content/uploads/2019/02/clot-club-doacs-8.jpg)
UPDATE ON THE DIRECT ORAL ANTICOAGULANTS (DOACs): WHERE ARE WE IN THE LABORATORY ALMOST TEN YEARS LATER? - DiaPharma
![Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation | Scientific Reports Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-93372-9/MediaObjects/41598_2021_93372_Fig1_HTML.png)
Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation | Scientific Reports
![Frontiers | Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation—A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation Frontiers | Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation—A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation](https://www.frontiersin.org/files/Articles/478395/fneur-10-00975-HTML/image_m/fneur-10-00975-g001.jpg)
Frontiers | Protocol for AREST: Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation—A Randomized Controlled Trial of Early Anticoagulation After Acute Ischemic Stroke in Atrial Fibrillation
![Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation](https://www.apsf.org/wp-content/uploads/newsletters/2017/Oct/images/NOAC_FIG1.png)
Perioperative Management of New Anticoagulants: Novel Drugs and Concepts - Anesthesia Patient Safety Foundation
![Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges | Journal of the American Heart Association](https://www.ahajournals.org/cms/asset/b8939236-6c55-4646-946f-998500325506/jah35265-fig-0001.png)